EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares, rose in value on Wednesday, June 18, with the stock price up by 1.25% to the previous day’s close as strong demand from buyers drove the stock to $8.92.
Actively observing the price movement in the last trading, the stock closed the session at $8.81, falling within a range of $8.62 and $9.14. The value of beta (5-year monthly) was 1.639. Referring to stock’s 52-week performance, its high was $13.98, and the low was $3.91. On the whole, EYPT has fluctuated by 46.23% over the past month.
With the market capitalization of EyePoint Pharmaceuticals Inc currently standing at about $613.80 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-07.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that EYPT’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of EYPT currently trading nearly 13.63% and 32.07% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 69.13, while the 7-day volatility ratio is showing 1.65% which for the 30-day chart, stands at 5.07%. Furthermore, EyePoint Pharmaceuticals Inc (EYPT)’s beta value is 1.64, and its average true range (ATR) is 0.57.
A comparison of EyePoint Pharmaceuticals Inc (EYPT) with its peers suggests the former has fared considerably weaker in the market. EYPT showed an intraday change of 1.25% in last session, and over the past year, it shrunk by -4.90%%.
Data on historical trading for EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) indicates that the trading volumes over the past 10 days have averaged 0.69 and over the past 3 months, they’ve averaged 826.89K. According to company’s latest data on outstanding shares, there are 68.81 million shares outstanding.
Nearly 13.08% of EyePoint Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 96.94% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.17 million shares as on 2025-05-30, resulting in a short ratio of 8.51. According to the data, the short interest in EyePoint Pharmaceuticals Inc (EYPT) stood at 1249.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 10.07 million. The stock has risen by 19.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EYPT stock heading into the next quarter.
